Entrada Therapeutics Inc. (TRDA)
TRDA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1689375/000168937526000011/0001689375-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TRDA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001689375 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $25.4M |
| Net income | -$143.8M |
| Operating income | -$157.9M |
| Net margin | -565.5% |
| Operating margin | -621.1% |
| Revenue growth | -87.9% |
| Cash | $90.4M |
| Total assets | $377.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 7.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these condensed consolidated financial statements are issued." | 10-Q 2026-11-05 |
| Cash and burn | $112.2M cash; operating cash flow -$34.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 39,150,334 (2026-10-31); 38,219,232 a year earlier; 33,368,078 three years earlier. | Cover page 2026-10-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.6M, sold $8.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $905K | -$39.7M | -$30.0M | $112.2M | No debt tags | $4.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $898K | -$42.8M | -$32.5M | $99.3M | No debt tags | $4.7M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $875K | -$39.7M | -$41.7M | $76.4M | No debt tags | $5.7M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $1.3M | -$39.2M | -$32.2M | $90.4M | No debt tags | $25.4M | 10-K 2026-02-26 |
| Q3 2025 2025-09-30 | $1.6M | -$44.1M | -$28.3M | $93.3M | No debt tags | $61.5M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $1.9M | -$43.1M | -$29.5M | $72.5M | No debt tags | $79.5M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $20.6M | -$17.3M | -$38.5M | $67.8M | No debt tags | $172.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $37.4M | $1.1M | -$31.6M | $101.2M | No debt tags | $210.8M | 10-K 2026-02-26 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-3 | S-3 | 2025-11-06 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 474 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.1% |
| 1 month | +4.7% |
| 3 months | -31.7% |
| Year to date | -50.5% |
| 1 year | -42.0% |
| From 52-week high | -68.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NGEN | NervGen Pharma Corp. | $1.82 | -3.19% | $195.9M |
| KROS | Keros Therapeutics Inc. | $10.03 | -2.62% | $196.8M |
| GLSI | Greenwich LifeSciences Inc. | $13.76 | -7.90% | $202.0M |
| SIGA | SIGA Technologies Inc. | $2.85 | +4.01% | $204.8M |
| RNAC | Cartesian Therapeutics Inc. | $6.08 | -4.25% | $185.5M |
| CYPH | Cypherpunk Technologies Inc. | $1.93 | +2.94% | $207.4M |
| NATR | Nature's Sunshine Products Inc. | $10.56 | +1.93% | $183.0M |
| YARW | Yarrow Bioscience Inc. | $13.93 | -22.74% | $212.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier